March 10, 2020
Grifols earns 'Excellent' rating in Profarma Plan for 18th consecutive year
- A participant in the Profarma Plan since 1991, Grifols received the highest possible rating in 2019 in recognition of its solid commitment to R+D+i
- Grifols increased its R+D+i investments in 2019 by 12.9% to EUR 329 million, allocating a total of EUR 1,500 million to this area over the last five years
- The Profarma Plan is jointly managed by the Spanish Ministry of Economy, Industry and Competitiveness and Ministry of Health, Social Services and Equality to boost the competitiveness of Spain’s pharmaceutical industry
- Grifols participates in Group A of the program, which includes firms with significant research activity and their own pharmaceutical manufacturing plant, or basic or pre-clinical research center
Barcelona, March 10, 2020 – Grifols (MCE: GRF, MCE: GRF.P y NASDAQ: GRFS), one of the world’s leading companies in the production of plasma-derived medicines and a pioneer in the research and development of alternative therapies that contribute to scientific and social progress, has received an “Excellent” rating in the 2019 Profarma Plan. Since 1991, the company has participated in Plan Profarma, promoted by the Ministry of Economy, Industry and Competitiveness and Ministry of Health, Social Services and Equality.
Grifols received the highest possible rating for the 18th consecutive year in Group A of the program, which includes companies with substantial research operations and their own pharmaceutical manufacturing plant or basic or pre-clinical research center. This distinction recognizes Grifols’ firm commitment to innovation and its robust R+D+i strategy, based on a holistic approach that includes both in-house initiatives and projects led by investees whose research complements the company’s operations.
This commitment represents an important investment effort. In 2019, Grifols intensified its net R+D+i investments, allocating EUR 329 million to this area, a 12.9% increase over the previous year and 6.5% of revenues. Over the last five years, Grifols has allotted EUR 1,500 million to R+D+i, which together with capital expenditures serves as an essential lever of long-term sustainable growth for the company.
In Spain, Grifols has three research centers in Barcelona, Bilbao and Zaragoza, and production facilities in Parets del Vallès (Barcelona) and Las Torres de Cotillas (Murcia). Moreover, the company expanded its workforce in Spain to 4,134 employees in 2019.
About PROFARMA 2017-2020
The 2017-2020 Profarma Plan is a joint initiative of the Ministry of Economy, Industry and Competitiveness and the Ministry of Health, Social Services and Equality aimed at boosting the competitiveness of the pharmaceutical industry in Spain through the modernization of the sector and support of activities that generate greater added value, such as activities in research, development and technological innovation, and industrial investments in production plants.